Home > GAMMAGARD Products > GAMMAGARD LIQUID IV

GAMMAGARD LIQUID IV

Learn more about intravenous (IV) administration of GAMMAGARD LIQUID

Protect life's moments with:



Selected Important Risk Information

  • The serious adverse reaction that occurred during the PI (IV administration) clinical trials was aseptic meningitis.
  • The most common adverse reactions observed in ≥ 5% of patients in the PI (IV administration) clinical trials were: Headache, fatigue, pyrexia, nausea, chills, rigors, pain in extremity, diarrhea, migraine, dizziness, vomiting, cough, urticaria, asthma, pharyngolaryngeal pain, rash, arthralgia, myalgia, oedema peripheral, pruritus, and cardiac murmur.

References: 1. GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% [Prescribing Information]. Westlake Village, CA: Baxter Healthcare Corporation. April 2014. 2. Church JA, Leibl H, Stein MR, et al, and the US-PID-IGIV 10%-Study Group. Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IVIG 10%] in patients with primary immunodeficiency. J Clin Immunol. 2006;26:388-395.


  • Your patients can get access to experienced Patient and Nurse Advocates, insurance and financial support, useful tools, and more.
    Find Out How
  • Infusion Training Get training support from our Nurse
    Advocates on intravenous and subcutaneous administration of GAMMAGARD LIQUID.

    Call 1-855-250-5111 to talk to a
    Nurse Advocate

You are now leaving GAMMAGARD.com

Shire is not responsible for the privacy policy, the content or the accuracy of any web site accessed through a link on the GAMMAGARD.com site. A link to other web sites does not constitute an endorsement of Shire of the linked site, its products or services.

The browser window or tab for GAMMAGARD.com will remain open underneath the new browser window or tab. To return to GAMMAGARD.com at any time, close this tab or window.

Return to
GAMMAGARD.com
Continue